Shaperon HY209 gel misses primary endpoint in Phase 2 atopic dermatitis trial

• Shaperon received the final clinical study report for its Phase 2 trial of HY209 gel in mild-to-moderate atopic dermatitis.
• Results have already been presented in topline form; the detailed report confirms the trial missed its main efficacy goal versus placebo.
• Secondary readouts showed limited, inconsistent signs of benefit, with no clear dose-response pattern across treatment groups.
• Safety was broadly comparable to placebo, with mostly mild-to-moderate adverse events; one serious event was judged unrelated to treatment.
• Plans call for a follow-on trial with revised endpoints, dosing, patient selection, and site oversight to support partnering and development strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shaperon Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930901331), on September 30, 2026, and is solely responsible for the information contained therein.